PAMILIA phase II study aims to determine whether the addition of HER2-targeted treatment increases the pathologic remission rate in HER2 negative (IHC1+ or 2+ (FISH/SISH-) but HER2-E BC according to PAM50. This evidence concerns the gene ERBB2 and breast cancer.